share_log

Novavax | SC 13D: Statement of acquisition of beneficial ownership by individuals-Himanshu H. Shah(6.70%),Shah Capital Management(6.66%), etc.

Novavax | SC 13D: Statement of acquisition of beneficial ownership by individuals

诺瓦瓦克斯医药 | SC 13D:超过5%持股股东披露文件
美股sec公告 ·  04/15 06:28
Moomoo AI 已提取核心信息
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary...Show More
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary course of business, with no current plans to influence or change the company's operations. The Reporting Persons may engage in discussions with Novavax's management or other stakeholders and may alter their investment strategy based on the company's performance and market conditions. The filing also includes a Joint Filing Agreement and a letter to the Board of Directors (BOD Letter) as exhibits.
2024年4月10日,Shah Capital Management, Inc.、Shah Capital Opportunity Fund LP和Himanshu H. Shah(统称为申报人)就其对Novavax, Inc.的重大投资向美国证券交易委员会(SEC)提交了附表13D。该文件显示,作为投资顾问的沙阿资本管理公司和合伙企业Shah Capital Opportunity Fund LP以及总裁兼首席Himanshu H. Shah Shah Capital的投资官已经收购了Novavax的大量股份。申报人通过Shah资本管理公司共拥有9,326,176股股票,通过Shah Cap...展开全部
2024年4月10日,Shah Capital Management, Inc.、Shah Capital Opportunity Fund LP和Himanshu H. Shah(统称为申报人)就其对Novavax, Inc.的重大投资向美国证券交易委员会(SEC)提交了附表13D。该文件显示,作为投资顾问的沙阿资本管理公司和合伙企业Shah Capital Opportunity Fund LP以及总裁兼首席Himanshu H. Shah Shah Capital的投资官已经收购了Novavax的大量股份。申报人通过Shah资本管理公司共拥有9,326,176股股票,通过Shah Capital Opportunity Fund LP共拥有8,700,000股股票,Himanshu H. Shah单独拥有9,383,335股股票,分别占已发行股份的6.66%、6.21%和6.70%。这些股票是在正常业务过程中出于投资目的而收购的,目前没有影响或改变公司运营的计划。申报人可以与Novavax的管理层或其他利益相关者进行讨论,并可能根据公司的业绩和市场状况改变其投资策略。该文件还包括一份联合申报协议和一封致董事会的信函(BOD 信函)作为证物。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息